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Abstract
Background: Oxidized low-density lipoproteins (oxLDL) and oxLDL-containing immune complexes (oxLDL-IC) contribute to
formation of lipid-laden macrophages (foam cells). It has been shown that oxLDL-IC are considerably more efficient than
oxLDL in induction of foam cell formation, inflammatory cytokines secretion, and cell survival promotion. Whereas oxLDL is
taken up by several scavenger receptors, oxLDL-IC are predominantly internalized through the FCc receptor I (FCc RI). This
study examined differences in intracellular trafficking of lipid and apolipoprotein moieties of oxLDL and oxLDL-IC and the
impact on oxidative stress.
Methodology/Findings: Fluorescently labeled lipid and protein moieties of oxLDL co-localized within endosomal and
lysosomal compartments in U937 human monocytic cells. In contrast, the lipid moiety of oxLDL-IC was detected in the
endosomal compartment, whereas its apolipoprotein moiety advanced to the lysosomal compartment. Cells treated with
oxLDL-IC prior to oxLDL demonstrated co-localization of internalized lipid moieties from both oxLDL and oxLDL-IC in the
endosomal compartment. This sequential treatment likely inhibited oxLDL lipid moieties from trafficking to the lysosomal
compartment. In RAW 264.7 macrophages, oxLDL-IC but not oxLDL induced GFP-tagged heat shock protein 70 (HSP70) and
HSP70B’, which co-localized with the lipid moiety of oxLDL-IC in the endosomal compartment. This suggests that HSP70
family members might prevent the degradation of the internalized lipid moiety of oxLDL-IC by delaying its advancement to
the lysosome. The data also showed that mitochondrial membrane potential was decreased and generation of reactive
oxygen and nitrogen species was increased in U937 cell treated with oxLDL compared to oxLDL-IC.
Conclusions/Significance: Findings suggest that lipid and apolipoprotein moieties of oxLDL-IC traffic to separate cellular
compartments, and that HSP70/70B’ might sequester the lipid moiety of oxLDL-IC in the endosomal compartment. This
mechanism could ultimately influence macrophage function and survival. Furthermore, oxLDL-IC might regulate the
intracellular trafficking of free oxLDL possibly through the induction of HSP70/70B’.
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Introduction
An early event in atherosclerosis is the engorgement of
macrophages with lipids. It is well established that activated
macrophagesbecomelipid-ladenfoam cellsbytakingupoxidatively
modified low-density lipoprotein (oxLDL), leading to the accumu-
lation of cholesteryl esters (CE) [1]. Circulating oxLDL elicits the
production of auto-immune antibodies, predominantly of the pro-
inflammatory IgG1 and IgG3 isotypes, resulting in the formation of
oxLDL-containing immune complexes (oxLDL-IC) [2,3,4]. While
both oxLDL and oxLDL-IC have been detected in human
atherosclerotic plaques [5], oxLDL-IC are considerably more
efficient than oxLDL in the induction of foam cell formation [6].
We and others have shown that human monocytic cells exposed to
oxLDL have reduced cell survival compared to those exposed to
oxLDL-IC [7,8]. Furthermore macrophages exposed to oxLDL-IC
result in the release of the pro-inflammatory and plaque
destabilizing factors that promote lesion progression [9,10,11].
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12534The internalization of lipids in macrophages occurs through
mechanisms involving different cell surface receptors. The macro-
phage scavenger receptors are a family of proteins which include
scavengerreceptorsclassA(macrophagescavengerreceptorIandII,
MSR-I and MSR-II), and class B (SR-BI and CD36). Macrophage
scavenger receptors from both classes bind modified LDL [12,13],
and mediate its delivery to lysosomes for processing and degradation
[14].Incontrast,oxLDL-ICarepredominantlyinternalizedthrough
the FCc receptorI (FCc RI)[15].However,thetemporal and spatial
intracellular localization of lipid and apolipoprotein moieties of
oxLDL-IC, and how trafficking of these moieties influences the
formation, activation and survival of foam cells are still obscure. In a
recent study we showed that in macrophages, internalized oxLDL-
IC induces a member of the HSP70 family, heat shock protein 70B’
(HSP70B’), which co-localizes with the lipid moiety of oxLDL-IC
[16]. In the current study we investigated the effect of HSP70 and
HSP70B’ on the advancement of internalized moieties of oxLDL-IC
to the lysosomal compartment.
Basedonexperimentalevidenceandclinicalstudies,oxidativeand
nitrosative stresses have been shown to be induced by atherosclerosis
risk factors and to contribute to the onset and development of
atherosclerotic vascular damage [17]. Reactive oxygen species
(ROS), as well reactive nitrogen species (RNS), are products of
normal cellular metabolism; however, cells of the immune system
produce both superoxide anion (O2
2) and nitric oxide (NO) during
the oxidative burst triggered during inflammatory processes [18].
The dynamic interactions between endogenous ROS/RNS and
intracellular signaling pathways may play a key role in the activation
of macrophages. It has been found that the generation of ROS and
RNS does not completely deplete intracellular antioxidants, rather
regulates the atherogenic process by modulating intracellular
signaling pathways affecting inflammatory cell adhesion, migration,
proliferation, and differentiation [19]. Nonetheless, overproduction
of ROS/RNS or a deficiency of enzymatic or non-enzymatic
antioxidants may cause biological damage to cellular lipids, proteins,
and DNA leading to cell death [20].
Mitochondria are both major source and target of oxidative
stress [21,22]. It has been suggested that mitochondrial damage in
early stage can predict ROS- and RNS-mediated atherosclerotic
lesions [23]. However, the differential effect of oxLDL and
oxLDL-IC on oxidative stress in macrophages is not fully
understood. In this study we investigated differences in trafficking
of internalized oxLDL and oxLDL-IC using fluorescently labeled
lipoprotein moieties. We also examined the effects of oxLDL and
oxLDL-IC on mitochondrial membrane potential and the
intracellular generation of hydrogen peroxide (H2O2) and NO.
Results
Characterization of labeled oxLDL and uptake by U937
cells
Oxidation of N-LDL modifies the lipoprotein particle and affects
its migration on agarose gel. Paragon Lipo Gel electrophoresis
systemwas usedtoverify particlemodification ofunlabeledaswellas
labeled oxLDL. Figure 1A shows the unlabeled oxLDL (lane 2) and
oxLDLlabeledwithDiI(lane3),DiO(lane4),andAlexa546(lane5)
migrated further toward the positive pole than N-LDL (lane 1).
To visualize the uptake of labeled oxLDL, U937 cells were
incubated with DiO-oxLDL, DiI-oxLDL, or Alexa 546-oxLDL for
5 h. Figure 1B shows that oxLDL labeled with any of the three
fluorescent labels was internalized in U937 cells, and that labeling
of either lipid or protein moiety of oxLDL resulted in comparable
internalization of oxLDL. To quantify internalization of labeled
lipid and protein moiety of oxLDL in a dose-dependent manner,
FACS analysis was performed. A mean of 82% of the cells showed
measurable levels of internalized labeled oxLDL. Figure 1C shows
that the mean fluorescence intensity in response to DiO-oxLDL,
DiI-oxLDL, and Alexa 546-oxLDL was dose dependent.
Localization of labeled lipoprotein moieties of oxLDL and
oxLDL-IC in endosomal compartment
To investigate localization of internalized labeled lipoprotein
moieties (lipids and apolipoproteins) of oxLDL and oxLDL-IC in the
endosomal compartment, transferrin labeled with Alexa 488 was
used as a marker for the early endosomal compartment. Transferrin
is typically transported into the cell through endosomal vesicles,
which recycle back to the cell surface. Cells were incubated
simultaneously with labeled transferrin, and with either labeled
oxLDL or oxLDL-IC. Cells treated with DiI-oxLDL (Fig. 2A, panels
a,b) or Alexa 546-oxLDL (Fig. 2B, panels a,b), showed co-localization
of lipid and apolipoprotein moieties of oxLDL with transferrin at
90 min, with an increase in uptake and co-localization with
transferrin (endosomal vescicles) at 5 h. For cells treated with labeled
oxLDL-IC, both the labeled lipid moiety (Fig. 2A, panel c) and
apolipoprotein moiety (Fig. 2B, panel c) of oxLDL-IC were found
associated with the cell membrane at 90 min. Interestingly, at 5 h
post treatment, labeled lipid and apolipoprotein moieties of oxLDL-
IC showed separate pathways. While internalized lipid moiety of
oxLDL-IC (DiI) co-localized with transferrin (Fig. 2A, panel d); the
internalized apolipoprotein moiety did not (Fig. 2B, panel d).
Localization of labeled lipoprotein moieties of oxLDL and
oxLDL-IC in lysosomal compartment
To determine whether oxLDL and oxLDL-IC trafficked to the
lysosomal compartment, Lyso Tracker-26 was used. This
fluorescent dye accumulates in cellular compartments with low
internal organelle pH and can be used to investigate the
biosynthesis and pathogenesis of lysosomes in live cells. For cells
treated with labeled oxLDL, both the lipid (Fig. 3A; panels a,b)
and apolipoprotein moieties (Fig. 3B; panels a,b) co-localized with
Lyso Tracker-26 at 90 min, with an increase of oxLDL
internalization at 5 h. For cells treated with labeled oxLDL-IC,
labeled lipid moiety (Fig. 3A, panel c) and apolipoprotein moiety
(Fig. 3B, panel c) of oxLDL-IC were found associated with the cell
membrane of living U937 cells at 90 min. However, at 5 h post
treatment, the internalized lipid and apolipoprotein moieties of
oxLDL-IC trafficked separately. While internalized apolipoprotein
moiety co-localized with Lyso Tracker-26 (Fig. 3B, panel d); the
internalized lipid moiety of oxLDL-IC (DiI) did not appear to
localize in the lysosomal compartment (Fig. 3A, panel d).
Lipid moieties of oxLDL and oxLDL-IC co-localize when
administered sequentially but not simultaneously
To determine the effect of co-incubation of oxLDL and oxLDL-
IC on lipoprotein uptake and trafficking, U937 cells were treated
simultaneously or sequentially with DiI-oxLDL-IC preceding DiO-
oxLDL treatment. Figure 4A shows that when labeled oxLDL-IC
and oxLDL were administered simultaneously their lipid moieties
did not appear to co-localize 5 h post treatment. However, when
administered sequentially with DiI-oxLDL-IC 2 h prior to DiO-
oxLDL treatment, the internalized lipid moieties of oxLDL and
oxLDL-IC co-localized. To investigate which labeled lipoprotein
moieties of oxLDL and oxLDL-IC trafficked to the lysosomal
compartment, Lyso Tracker-22 was used to probe the lysosomes.
Figure 4B shows that after simultaneous incubation with labeled
oxLDLandoxLDL-IC(upperpanel),theinternalizedlipidmoietyof
oxLDL (DiO) co-localized with Lyostracker-22; however, the
LDL Immune Complex Trafficking
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localize with either DiO or Lyso Tracker-22. Interestingly, when
labeled oxLDL-IC and oxLDL were added sequentially (Fig. 4B,
lower panels); the internalized lipid moieties of oxLDL (DiO) and
oxLDL-IC(DiI)wereco-localized,butnotwiththeLysoTracker-22.
Lipid moiety of oxLDL-IC but not oxLDL co-localizes with
induced HSP70/70B’ in endosomal vesicles
We have recently shown that in RAW 267.4 cells both HSP70-
GFP and HSP70B’-GFP are induced by oxLDL-IC but not
oxLDL [16]. Here we show that DiI-oxLDL-IC co-localized with
Alexa 633-transferrin and HSP70-GFP (Fig. 5A) or HSP70B’-GFP
(Fig. 5B). RAW 267.4 cells treated with DiI-oxLDL showed co-
localization of the lipid moiety (DiI) of oxLDL with labeled
transferrin in HSP70-GFP- transfected cells (Fig. 5A) or HSP70B’-
GFP-transfected cells (data not shown).
Differential effect of oxLDL and oxLDL-IC on
mitochondrial membrane potential and ROS/RNS
production
Mitochondrial membrane potential and generation of ROS and
RNS were examined using MitoTrackerH Deep Red FM, CM-
H2DCFDA and DAF-FM diacetate, respectively. Mitochondrial
membrane potential was decreased in cells treated with oxLDL
compared to cells treated with oxLDL-IC, KLH-IC, or IMDM
vehicle (Fig. 6A,B). Cells treated with oxLDL-IC, KLH-IC, or
IMDM vehicle maintained mitochondrial membrane potential at
all time points (data not shown). Additionally oxLDL induced
corresponding increase in H2O2 levels (Fig. 6A) and NO levels
(Fig. 6B). The generation of H2O2 and NO in response to oxLDL
occurred as early as 30 min post treatment (data not shown) and
increased over time. There was no difference in H2O2 and NO
generation in response to oxLDL-IC, KLH-IC or IMDM vehicle
at all time points (data not shown).
Discussion
Investigating the mechanisms controlling the intracellular
transport of lipid and apolipoprotein moieties of oxLDL and
oxLDL-IC in macrophages is central in understanding foam cell
formation, activation, and survival. In this study we examined the
uptake of oxLDL and oxLDL-IC by human monocytic cells and
analyzed differences in the intracellular trafficking of their lipid
and apolipoprotein moieties. We showed that both lipid and
protein moieties of oxLDL were localized in endosomal and
Figure 1. Characterization of oxLDL labeling and uptake by U937 cells. (A) Migration of fluorescently labeled oxLDL analyzed by agarose gel
electrophoresis: lane 1: native LDL, lane 2: oxLDL, lane 3: DiI-oxLDL, lane 4: DiO-oxLDL, lane 5: Alexa 546-oxLDL, lane 6: LPDS. (B) Uptake of
fluorescently labeled oxLDL. U937 cells were treated with labeled oxLDL: DiO-oxLDL, DiI-oxLDL, or Alexa 546-oxLDL (24 mg/ml) for 5 h then fixed with
4% formaldehyde and visualized in sealed capillaries using confocal microscopy. (C) FACS analysis showing dose-dependent uptake of labeled oxLDL
90 min post treatment in U937 cells. Each data point represents the mean 6 range of duplicate determinations (1610
4 cells/determination), and data
presented are representative of four independent experiments.
doi:10.1371/journal.pone.0012534.g001
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apolipoprotein moieties of oxLDL-IC trafficked separately. The
internalized lipid moiety of oxLDL-IC localized in the endosomal
vesicles, whereas the apolipoprotein moiety advanced to the
lysosmal compartment. Cells treated with oxLDL-IC prior to
addition of oxLDL demonstrated co-localization of internalized
lipid moieties from both oxLDL and oxLDL-IC. This sequential
treatment with oxLDL-IC followed by oxLDL likely inhibited
oxLDL lipid moieties from trafficking to the lysosomal compart-
ment, which suggests that oxLDL-IC might regulate intracellular
trafficking of free oxLDL.
Intriguingly, the lipid moiety of oxLDL-IC, but not oxLDL, co-
localized in the endosomal compartment with induced HSP70/
70B’. This suggests that HSP70 family members might prevent the
degradation of the internalized lipid moiety of oxLDL-IC by
delaying its advancement to the lysosome. The results also showed
that mitochondrial membrane potential was decreased, and the
generation of reactive oxygen and nitrogen species was increased
in monocytic cells treated with oxLDL compared to oxLDL-IC
and control immune complexes. It has been previously shown that
constitutive and inducible HSP70s contribute to oxidative
resistance evoked by heat shock or ethanol [24]. The current
data provide further mechanistic support to our argument that
oxLDL-IC are considerably more efficient than oxLDL in
induction of lipid accumulation [3,6,25], and in promotion of cell
survival [7].
Modified forms of LDL, including oxLDL and oxLDL-IC, have
been detected in circulation and in atheromatous plaques [5,26],
and have been shown to contribute to macrophage lipid
accumulation in the vessel wall [5,26,27,28]. The accumulation
of cholesterol in macrophages in the form of cytoplasmic lipid
droplets is an early step in the formation of atherosclerotic lesions
[28]. Continual macrophage uptake of oxLDL increases the
accumulation of CE, resulting in lysosomal disturbance and
ultimately apoptosis [29,30]. In the present study we corroborated
that the uptake of both lipid and protein moieties of oxLDL was
dose dependent in U937 cells, and that both lipid and protein
moieties of oxLDL were internalized in endosomal vesicles and
localized in the lysosomal compartment.
Although the oxLDL used to prepare oxLDL-IC was the same
preparation as that of the free oxLDL, the trafficking of the lipid
and protein moieties of oxLDL was different when the lipoprotein
presented to cells free or as a part of an immune complex.
Oxidized LDL, when free, binds to a number of cell-surface
receptors, including scavenger receptors SR-A and CD36 which
are the critical contributors to modified lipoprotein uptake in
macrophages [1,31,32]. In contrast, oxLDL-IC are predominantly
internalized through the Fcc RI [15], resulting in an increased
Figure 2. Localization of labeled lipoprotein moieties of oxLDL
and oxLDL-IC in endosomal vesicles. U937 cells were treated with
endosomal marker (Alexa 488-transferrin, green) and with either DiI-
labeled lipid moiety (red) (A), or Alexa 546-labeled protein moiety (red)
(B) for 90 min and 5 h. Cells were treated with Alexa 488-transferrin
(5 mg/ml) and with either labeled oxLDL (24 mg/ml) or labeled oxLDL-IC
(32 mg/ml), fixed with 4% formaldehyde, suspended in sealed capillaries
and visualized using Zeiss LSM 510 laser scanning confocal microscope.
Arrows point at co-localization of lipid and apolipoprotein moities of
oxLDL and oxLDL-IC with Alexa 488-transferrin.
doi:10.1371/journal.pone.0012534.g002
Figure 3. Localization of labeled lipoprotein moieties of oxLDL
and oxLDL-IC in lysosomal compartment. U937 cells were treated
with either DiI-labeled lipid moiety (red) (A), or Alexa 546-labeled
protein moiety (red) (B) for 90 min and 5 h, with lysosomal marker
(Lyso Tracker Green DND-26, 50 nM) applied for the last 30 min of
incubation. Cells were treated with labeled oxLDL and oxLDL-IC at
18 mg/ml and 24 mg/ml, respectively. Live cells were washed with DPBS
then suspended in sealed capillaries and visualized using confocal
microscopy. Arrows point at co-localization of lipid and apolipoprotein
moieties of oxLDL and oxLDL-IC with lysosomal compartment.
doi:10.1371/journal.pone.0012534.g003
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exposed to oxLDL alone [3,25]. The data presented in this study
showed that both lipid and apolipoprotein moieties of oxLDL-IC
were still associated with the cell membrane of U937 cells 90 min
post treatment. After 5 h the lipid and apolipoprotein moieties of
oxLDL-IC were internalized, however they took separate paths
inside the cells. Interestingly, the lipid moiety of oxLDL-IC
localized in the endosomal vesicles, while the apolipoprotein
moiety trafficked directly to the lysosomal compartment. These
results suggest that the internalized lipid moiety of oxLDL-IC may
have been ‘‘trapped’’ in the endosomal vesicles, whereas the
apolipoprotein moiety of oxLDL-IC was rapidly directed to the
lysosomal compartment for degradation.
It has been previously shown that human macrophages
incubated with LDL-IC 22 h prior to addition of native LDL
for another 20 h resulted in increase in intracellular accumulation
of ‘‘undegraded’’ LDL, and 90% of the accumulated CE were
attributed to the initial incubation with LDL-IC [33]. Here, we
showed that when cells were incubated with oxLDL-IC and
oxLDL simultaneously, their internalized lipid moieties did not
appear to co-localize; however, when cells were treated with
oxLDL-IC for 2 h prior to addition of oxLDL, internalized lipid
moieties of both oxLDL and oxLDL-IC co-localized. This
sequential incubation interfered with the lipid moiety of oxLDL
trafficking to the lysosomal compartment. Typically and as
demonstrated in this study, free modified lipoproteins internalized
by macrophages are swiftly trafficked to lysosomes [34].
Simultaneous incubation of oxLDL with oxLDL-IC resulted in
trafficking of the lipid moiety of oxLDL to the lysosmal
compartment with almost no interference of oxLDL-IC.
These results suggest that stimulation with oxLDL-IC may
regulate the trafficking and degradation of internalized oxLDL
possibly through generating a signaling cascade to redirect the
lipid moiety of free oxLDL away from lysosomes. Alternatively,
the delay or prevention of trafficking to the lysosomal compart-
ment of lipoprotein constituents may be attributed to chaperon
binding and/or entry into intracellular vesicular recycling
compartments destined for the cell surface. It has been shown
for example that in dendritic cells antigens endocytosed by Fcc
RIIB access a non-degenerative intracellular vesicular compart-
ment that recycles to the cell surface facilitating antigen
presentation to lymphocytes [35]. Since HSPs are molecular
Figure 4. Lipid moieties of oxLDL and oxLDL-IC co-localize when administered sequentially but not simultaneously. U937 cells were
incubated with DiI-oxLDL-IC (red) and DiO-oxLDL (green) (A) sequentially and (B) in parallel in U937 cells. They were incubated for a total of 5 h.
Sequential experiment involved 2 h incubation of oxLDL-IC (32 mg/ml), prior to addition of oxLDL (24 mg/ml) for 3 h. Lyso Tacker Blue DND-22,
(50 nM) was used and applied for the last 30 min of incubation. Cells were fixed with 4% formaldehyde, suspended in sealed capillaries and visualized
using Zeiss LSM 510 Laser scanning confocal microscope. Arrows point at co-localization of oxLDL in the lysosomal compartment in the upper panel,
and the co-localization of oxLDL and oxLDL-IC in the lower panel.
doi:10.1371/journal.pone.0012534.g004
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exposed hydrophobic residues [36], HSP70/70B’ could possibly
be involved in the ‘‘sequestration’’ of lipoprotein constituents in
the endosomal compartment as shown in the current study.
Interestingly, it has been recently shown that endocytosed
recombinant HSP70 stabilizes lysosomes by binding to an
endolysosomal anionic phospholipid bis(monoacylglycero)pho-
sphate, an essential co-factor for lysosomal sphingomyelin
metabolism [37].
In macrophages and dendritic cells, it has been also shown that
complexes formed by binding of the lipid-binding protein, b2-
glycoprotein I (b2GPI), to oxLDL or liposomes containing
phospholipids, facilitate processing and presentation of a cryptic
b2GPI’s epitope to autoreactive T cells from antiphospholipid
syndrome patients [38]. Interestingly, in the presence of anti-
b2GPI IgG, b2GPI-oxLDL complexes were shown to be rapidly
incorporated into lysosomes, while the non-complexed b2GPI
stagnated in late endosomes [39]. The expression of the receptors
CD36 and FCc RI were up-regulated in response to b2GPI-
oxLDL complexes in combination with anti-b2GPI IgG. Efficient
presentation of the cryptic determinants by monocytes was found
to be mediated by FCc RI [40].
It has been shown that excess production of ROS and RNS has
been implicated with vascular lesion formation and functional
defect [41,42,43]. It is now clear that H2O2 and NO produced by
the respiratory burst function as second messengers and activates
major signaling pathways [18]. For example, H2O2 activates both
the nuclear factor-kB and activator protein-1 transcription factors,
both control the inducible expression of genes regulating
inflammatory responses [44]. Our present data demonstrated
that, in cells treated with free oxLDL, mitochondrial membrane
potential decreased and intracellular H2O2 and NO significantly
increased compared to cells treated with oxLDL-IC or KLH-IC.
Our data are in agreement with data by Deng et al [45], who
showed that differentiated U937 cells treated with oxLDL
exhibited mitochondrial membrane depolarization and increased
H2O2 and NO levels by 15 min post treatment. Here we
additionally show that cells exposed to oxLDL-IC maintained
unvarying mitochondrial membrane potential, and exhibited no
change in their baseline levels of H2O2 and NO over time.
In an earlier study we examined the effects of oxLDL compared
to oxLDL-IC on global gene expression in U937 cells using
microarray analysis [46]. The data revealed that levels of
expression of genes encoding superoxide dismutase 2 (SOD2)
was up-regulated 71-fold in response to oxLDL-IC compared to
vehicle. SOD2 is a principal scavenger enzyme in mitochondrial
matrix, which protects cells from oxidative stress by detoxifying
superoxide generated in mitochondrial respiration by dismutation.
In contrast, heme oxygenase 1 (HMOX1) was the gene with the
greatest level of increase in response to oxLDL [46]. HMOX1
induction is known to lead to an increase in catalytic free iron
release and it has been suggested that HMOX1 expression can be
increased several fold by stimuli that induce cellular oxidative
stress, including oxidized LDL [47,48]. Our present data
Figure 5. Lipid moiety of oxLDL-IC but not oxLDL co-localizes with induced HSP70/70B’ in endosomal vesicles. RAW 264.7 cells were
transfected with HSP70-GFP (A) or HSP70B’-GFP (B), then treated with DiI-oxLDL (24 mg/ml), DiI-oxLDL-IC (32 mg/ml), or DPBS vehicle in serum-free
DMEM for 3 h. Alexa 633-transferrin (10 mg/ml) was then added for an additional 2 h. Cells were then fixed with 4% formaldehyde, washed with
DPBS, and visualized using confocal microscopy.
doi:10.1371/journal.pone.0012534.g005
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mitochondrial membrane potential and increased H2O2 levels
compared to oxLDL-IC, KLH-IC immune complexes. Cells
treated with immune complexes maintained unvarying mitochon-
drial membrane potential. These results suggest that, in human
macrophages, free oxLDL and oxLDL-IC could be involved in the
differential regulation of mitochondrial respiratory chain function
and possibly influencing foam cell activation and survival.
In conclusion our current data showed that internalized lipid
and apolipoprotein moieties of oxLDL-IC trafficked to separate
cellular compartments, and that oxLDL-IC can regulate the
trafficking and metabolism of internalized free oxLDL. The results
also showed that cells treated with oxLDL and oxLDL-IC
regulated mitochondrial membrane potential and H2O2 produc-
tion differentially. Our current findings may contribute to future
development of therapeutics targeting certain aspects of lipopro-
tein trafficking in macrophages and foam cells.
Materials and Methods
Cells
The human monocytic cell line U937 was obtained from the
American Type Culture Collection (Manassas, VA) (ATCC CRL-
1593.2). This line is a monocytic lymphoma cell line, which
originates from resident macrophages [49]. Cells were maintained
in Iscove’s modified Dulbecco’s medium (IMDM) supplemented
with 10% fetal bovine serum, 100 units/ml penicillin, and 50 mg/
ml streptomycin at 37uC, 5% CO2. Unless otherwise indicated,
cells were seeded at 2.5610
5 cells/250 ml medium in 48-well
plates, and incubated in serum-free medium in the presence of
interferon-gamma (IFN-c) (200 ng/ml) (EMD, Bioscience, San-
diego, CA) for 18 h prior to addition of experimental treatments.
RAW 264.7 mouse macrophage-like cells (ATCC TIB-71
TM) were
grown in Dulbecco modified Eagle medium (DMEM) supple-
mented with 10% FBS, penicillin and streptomycin at 37uC, 5%
CO2. For routine maintenance, RAW 264.7 cells were grown to
80% confluence and sub-cultured every two days.
Lipoprotein Isolation and Oxidation
LDL (d=1.019 to 1.063 g/ml) was isolated from plasma of
donors who were free from clinically apparent disease, and
oxidatively modified using Cu2
+ as described previously
[46,50,51]. The degree of LDL oxidation was monitored contin-
uously by fluorescence emission at 234 nm using a fluorescence
spectrophotometer (SLM-AMINCOH Series 2, Spectronic Instru-
ments, Rochester, NY) and stopped when the fluorescence values
reached the peak ($1.1 fluorescence units). The oxidative
modification of LDL was evaluated by quantitation of conjugated
dienes [50,51]. LDL modification was verified by particle migration
on the ParagonH Electrophoresis System (Beckman Coulter,
Fullerton, CA). Briefly, lipoproteins (5 mg protein each) were loaded
onto the gel and subjected to electrophoresis for 30 min at 100 V.
Particle modification was verified by migration of the oxLDL
relative to native LDL (N-LDL) samples.
Preparation of oxLDL-IC Immune Complexes
Immune complexes containing oxLDL were prepared with
human oxLDL and human anti-oxLDL antibodies as described
Figure 6. Differential effect of oxLDL and oxLDL-IC on
mitochondrial membrane potential and ROS/RNS production.
U937 cells were grown in phenol red-free IMDM supplemented with
10% fetal bovine serum, 100 units/ml penicillin, 50 mg/ml streptomycin,
and IFN-c (200 ng/ml) for 18 h then treated with oxLDL (90 mg/ml),
oxLDL-IC, KLH-IC (120 mg/ml) in IMDM up to 5 h. (A) Detection of H2O2:
Cells were treated with CM-H2DCFDA (5 mM), and Mito Tracker
(100 nM) for 30 and 15 min, respectively, prior to conclusion of
incubation time with the treatments (5 h). Cells were fixed, suspended
in sealed capillaries and visualized using Zeiss LSM 510 Laser scanning
confocal microscope. (B) Detection of NO: IFN-c-treated cells were
incubated with L-arginine (100 mM), and DAF-FM diacetate (10 mM) for
1 h, then washed with IMDM twice. Cells were then treated with oxLDL,
oxLDL-IC, and KLH-IC as indicated above. Mito Tracker (100 nM) were
added 15 min prior to conclusion of incubation time with the
treatments (90 min). Live cells were washed, suspended in sealed
capillaries and visualized using Zeiss LSM 510 Laser scanning confocal
microscope.
doi:10.1371/journal.pone.0012534.g006
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plexes (KLH-IC) were used as control immune complexes because
KLH has a molecular weight comparable to LDL and because it
can engage Fcc receptors similar to oxLDL-IC but does not
contain lipoproteins. KLH-IC were also prepared as described
previously [9,46]. After precipitation, immune complexes were re-
suspended in Dulbecco’s phosphate buffered saline (DPBS) and
the concentrations of total protein were determined using the BCA
protein assay (Pierce, Thermo Scientific, Rockford, IL). Labeled
oxLDL-IC were prepared with fluorescently labeled oxLDL.
Labeling of oxLDL with Lipophilic Fluorescent Dyes
Fluorescent labeling of the lipid moiety of oxLDL was
performed as described previously [52] with modification. Briefly,
oxLDL (1.0 ml, 1.0 mg protein) was mixed with lipoprotein-
deficient serum (LPDS, 1.0 ml), and then filter (0.22 mm)
sterilized. A 50-ml aliquot of DiI:1,19-dioctadecyl-3,3,39,3-tetra-
methylindocarbocyanine perchlorate (DiI) or DiO:3,39-dioctade-
cyloxacarbocyanine perchlorate (DiO) (Invitrogen, Carlsbad, CA),
each 3.0 mg/ml in DMSO (Sigma, St. Louis, MO), was added to
the oxLDL-LPDS mixture. The mixture was gently mixed and
incubated at 37uC for 8 h. To isolate the labeled oxLDL, the
density of the solution containing the fluorescent labeled LDL was
raised to 1.225 g/ml with solid KBr, and the solution loaded into a
polymer ultracentrifuge tube (13-ml tube, Beckman). Tubes were
then filled with a saline solution whose density was adjusted to
1.21 g/ml with solid KBr. The labeled LDL was then floated out
of the mixture by ultracentrifugation with a Beckman SW41 Ti
rotor at 41,000 rpm, 36 h, 4uC. The labeled oxLDL floating at the
top of the tube was aspirated and the density of this solution was
raised to 1.225 g/ml and the solution was again centrifuged at
41,000 rpm, 36 h, 4uC. The top layer was aspirated, dialyzed
against NaCl-EDTA solution (150 mM NaCl/300 mM EDTA),
pH 8.6) then filter-sterilized and stored at 4uC. The concentration
of protein in the labeled oxLDL was determined using the BCA
protein assay, and the differential electrophoretic mobility of
labeled oxLDL in agarose was determined as described above.
Fluorescent Labeling of the Protein Moiety of oxLDL
Fluorescent labeling of the protein moiety of oxLDL was
performed using Alexa FluorH 546 carboxylic acid, succinimidyl
ester (Invitrogen) (Alexa 546) according to manufacturer’s
protocol. Briefly, oxLDL (2 mg protein) was dialyzed in 0.1 M
NaHCO3 buffer, pH 8.3. Alexa 546 (1 mg/100 mL DMSO) was
then added to oxLDL solution (25 mL:2 ml, respectively). This
solution was incubated for 1 h at room temperature in the dark.
The protein-dye conjugate was separated from free unbound dye
by PD-10 column. The sample was eluted using PBS; 0.5-ml
fractions were collected. The peak fractions were pooled, dialyzed
against NaCl-EDTA solution, and then filter-sterilized and stored
at 4uC. Protein concentration was determined using BCA protein
assay and differential migration of labeled oxLDL was determined
as described above.
Fluorescence Activated Cell Sorting (FACS)
Internalization of fluorescently labeled oxLDL was evaluated by
flow cytometry. Cells (8610
5 cells/ml) were serum starved and
IFN-c treated as described above. Cells were then treated with
DiO-oxLDL, DiI-oxLDL, or Alexa 546-oxLDL (5, 10, 25, or
50 mg/ml) for 90 min. Cells were then washed three times with
DPBS, with propidium iodide added to the last wash for dead cell
exclusion. Cells were then analyzed by fluorescence activated cell
sorting with a Becton Dickinson FACSAria Cell Sorter (BD
Bioscience, San Jose, CA).
Expression of GFP-tagged human HSP70 and HSP70B’ in
RAW 264.7 cells
HSP70-GFP and HSP70B’-GFP expression vectors were
prepared and inserted into RAW 264.7 cells according to the
protocol described in our recent study [16].
Fluorescent Labeling of Transferrin for Tracking of
Labeled Lipoprotein Moieties in Endosomal
Compartment
Transferrin was labeled using Alexa FluorH 488 Protein
Labeling Kit or Alexa FluorH 633 Protein Labeling Kit
(Invitrogen) according to manufacturer’s protocol. The degree of
labeling was calculated and found to be 3.11 mole of Alexa FluorH
dye per mole of transferrin. U937 cells (1610
6 cells/ml) were
simultaneously treated with Alexa 488-transferrin (5 mg/ml) and
with either DiI-labeled lipid moiety or Alexa 546-labeled protein
moiety of oxLDL and oxLDL-IC for 90 min and 5 h. Cells were
treated with labeled oxLDL (24 mg/ml) or labeled oxLDL-IC
(32 mg/ml). Higher protein concentration of oxLDL-IC was used
as compared to oxLDL to normalize the amount of oxLDL
administered to the cells. Cells were then pelleted, fixed with 4%
formaldehyde, then washed three times with DPBS. Cells were
then suspended in 100 ml DPBS and 10-ml aliquots were loaded in
10-ml glass capillaries (Idaho Technology, Salt Lake City, UT) as
described previously [53]. The capillaries were sealed and cells
visualized using confocal microscopy (Zeiss LSM 510 Meta Laser
Scanning Confocal Microscope, Carl Zeiss MicroImaging, Inc.,
Thornwood, NY).
RAW 264.7 cells transfected with HSP70-GFP or HSP70B’-
GFP were plated in sterile glass bottom 96-well plates (MatTek
Corporation; Ashland, MA), then treated with DiI-oxLDL (24 mg/
ml) or DiI-oxLDL-IC (32 mg/ml) in serum-free DMEM for 3 h at
37uC, 5% CO2. Alexa 633-transferrin (10 mg/ml) was then added
for an additional 2 h. Cells were then fixed with 4% formalde-
hyde, washed three times with DPBS, and visualized using
confocal microscopy.
Tracking of Labeled Lipoprotein Moieties in Lysosomal
Compartment
U937 cells were treated with labeled oxLDL (18 mg/ml) or
labeled oxLDL-IC (24 mg/ml) for 90 min and 5 h. Cells were
treated with 50 nM Lyso Tracker Green DND-26 (Invitrogen)
(Lyso Tracker-26) 30 min prior to conclusion of incubation time
with labeled oxLDL and oxLDL-IC. Live cells were then washed
three times in serum free IMDM, suspended in 100 ml IMDM,
and 10-ml aliquots were loaded in capillaries and sealed as
described above. The live cells were visualized using Zeiss LSM
510 Meta Confocal Microscope.
Tracking of Labeled Lipoprotein Moieties of oxLDL and
oxLDL-IC Administered Simultaneously or Sequentially
U937 cells were treated with DiO-oxLDL (24 mg/ml) and DiI-
oxLDL-IC (32 mg/ml) in parallel for 5 h. In comparison studies,
cells were incubated sequentially with DiI-oxLDL-IC for 2 h
followed by DiO-oxLDL for an additional 3 h. To determine if the
parallel or sequential incubation of labeled lipoproteins resulted in
localization of the fluorescent labels within the lysosomal
compartment, Lyso Tracker Blue DND-22 (Invitrogen) (Lyso
Tracker-22) was used. This tracker is a blue fluorescent dye that
stains acidic compartment in live cells with excitation/emission
maxima 373/422 nm. U937 cells were treated with 50 nM of
Lyso Tracker 30 min prior to conclusion of incubation time with
labeled oxLDL and oxLDL-IC. Live cells were then washed three
LDL Immune Complex Trafficking
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ml aliquots were loaded into capillaries and sealed as described
above. The live cells were visualized using a Zeiss LSM 510 Meta
Confocal Microscope.
Detection of Mitochondrial Membrane Potential and
Changes in ROS and RNS
MitoTrackerH Deep Red FM (Invitrogen) (1 mM in DMSO)
was used to probe the mitochondria. This dye passively diffuses
across the plasma membrane and accumulates in active mito-
chondria, dependent upon membrane potential. For detection of
ROS, 5-(and-6)-chloromethyl-29,79-dichlorodihydrofluorescein di-
acetate, acetyl ester (CM-H2DCFDA) (Invitrogen) was used to
detect the generated intracellular H2O2. CM-H2DCFDA is a cell-
permeant indicator that is not fluorescent until removal of the
acetate groups by intracellular esterases and oxidation occurs.
CM-H2DCFDA (5 mM) was prepared in DMSO according to
manufacturer’s protocol. U937 cells (4610
5 cells/ml) were
incubated in phenol red-free IMDM supplemented with 10%
fetal bovine serum, 100 units/ml penicillin, 50 mg/ml streptomy-
cin, and IFN-c (200 ng/ml) for 18 h prior to addition of
experimental treatments. Cells were treated with oxLDL (90 mg/
ml), oxLDL-IC, KLH-IC (120 mg/ml) in IMDM for 30 min,
90 min, and 5 h. Cells were treated with CM-H2DCFDA (5 mM),
and Mito Tracker (100 nM) for 30 and 15 min, respectively, prior
to conclusion of incubation time with treatments. Cells were then
fixed and visualized using confocal microscopy.
For detection of RNS, 4-amino-5-methylamino-29,79-difluro-
fluorescein diacetate (Invitrogen) was used to detect the generated
intracellular nitric oxide (NO). DAF-FM diacetate is not
fluorescent until it is de-acetylated by intracellular esterases and
reacts with NO to form a fluorescent benzotrizole. DAF-FM
diacetate (5 mM) was prepared in DMSO according to manufac-
turer’s protocol. U937 cells were incubated with L-arginine
(100 mM) in DPBS and DAF-FM diacetate (10 mM) for 1 h, and
then cells were washed two times with serum and phenol red-free
IMDM. Cells were treated with oxLDL (90 mg/ml), oxLDL-IC,
KLH-IC (120 mg/ml) in IMDM for 30 min, 90 min, and 5 h.
Fifteen minutes prior to conclusion of incubation time with
treatments cells were treated with Mito Tracker (100 nM). Live
cells were then washed twice with IMDM visualized using confocal
microscopy.
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